Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Over 100 posts by our resident bashing team in the last week

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Nov 15, 2024 7:04pm

72 Views

Post# 36315949

RE:Over 100 posts by our resident bashing team in the last week

utter BS Peladan... ONCY could have run a Phase III 7 years ago... and if they'd repeated the results from IND-213, they'd already be treating patients...

Point the finger at the stellar ONC management team.. They have wasted the opporuntity to bring this to market, and you pumpers are blind to the point of delerium.

So given the low pps, you must be getting all giddy like Canaduh and adding a bit more... LOL

If you don't want to admit your'e backing a donkey, so be it... Hope you're looking forward to the RS in the spring.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario